Abstract
Almost all curative cancer therapies involve multi-drug combinations. The development of new combinations currently focuses on identifying instances of synergistic pharmacological interaction. Historically successful curative therapies were developed by experimentation in humans using different criteria but the mechanistic basis of these successful combinations has not been investigated in detail. Here we use isobologram analysis to score pharmacological interaction and clone-tracing and CRISPR screening to measure cross-resistance among the five drugs comprising R-CHOP, a combination therapy that frequently cures Diffuse Large B-Cell Lymphomas. We find that R-CHOP drugs exhibit very low cross-resistance but no synergy; some two-way interactions are even antagonistic. These data provide direct evidence for the 50-year old hypothesis that a curative cancer therapy can be constructed on the basis of non-overlapping drug resistance rather than pharmacological interaction.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
